BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35501997)

  • 1. In vitro cytotoxicity and docking study of novel symmetric and asymmetric dihydropyridines and pyridines as EGFR tyrosine kinase inhibitors.
    Mansour B; Bayoumi WA; El-Sayed MA; Abouzeid LA; Massoud MAM
    Chem Biol Drug Des; 2022 Jul; 100(1):121-135. PubMed ID: 35501997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
    Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
    Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7/HepG2 cytotoxicity: Synthesis, EGFR inhibitory effect, and metabolic stability.
    Ihmaid SK; Alraqa SY; Aouad MR; Aljuhani A; Elbadawy HM; Salama SA; Rezki N; Ahmed HEA
    Bioorg Chem; 2021 Jun; 111():104835. PubMed ID: 33798850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, In Vitro Evaluation and Molecular Docking Studies of Novel Thiophenyl Thiazolyl-Pyridine Hybrids as Potential Anticancer Agents.
    Ashmawy FO; Gomha SM; Abdallah MA; Zaki MEA; Al-Hussain SA; El-Desouky MA
    Molecules; 2023 May; 28(11):. PubMed ID: 37298747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, Anticancer Screening of Some Novel Trimethoxy Quinazolines and VEGFR2, EGFR Tyrosine Kinase Inhibitors Assay; Molecular Docking Studies.
    Altamimi AS; El-Azab AS; Abdelhamid SG; Alamri MA; Bayoumi AH; Alqahtani SM; Alabbas AB; Altharawi AI; Alossaimi MA; Mohamed MA
    Molecules; 2021 May; 26(10):. PubMed ID: 34069962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study.
    El-Sayed MA; El-Husseiny WM; Abdel-Aziz NI; El-Azab AS; Abuelizz HA; Abdel-Aziz AA
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):199-209. PubMed ID: 29251017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
    Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
    Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
    AboulWafa OM; Daabees HMG; Badawi WA
    Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives.
    Alkamaly OM; Altwaijry N; Sabour R; Harras MF
    Arch Pharm (Weinheim); 2021 Apr; 354(4):e2000351. PubMed ID: 33252142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
    Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
    Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
    Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
    Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
    Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
    Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, Synthesis, and Biological Evaluation of Novel Dihydropyridine and Pyridine Analogs as Potent Human Tissue Nonspecific Alkaline Phosphatase Inhibitors with Anticancer Activity: ROS and DNA Damage-Induced Apoptosis.
    Khan NA; Rashid F; Jadoon MSK; Jalil S; Khan ZA; Orfali R; Perveen S; Al-Taweel A; Iqbal J; Shahzad SA
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis,
    Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
    Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and mechanistic studies of novel imidazo[1,2-a]pyridines as anticancer agents.
    Ismael AS; Amin NH; Elsaadi MT; Abdel-Rahman HM
    Bioorg Chem; 2022 Nov; 128():106042. PubMed ID: 35878430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, Synthesis and In-Silico Studies of Piperidine-Dihydropyridine Hybrids as Anticancer Agents.
    Rejinthala S; Endoori S; Thumma V; Mondal T
    Chem Biodivers; 2024 Apr; 21(4):e202301456. PubMed ID: 38366873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.